PMC:7242007 / 3675-4395 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"225","span":{"begin":60,"end":68},"obj":"Species"},{"id":"226","span":{"begin":137,"end":145},"obj":"Species"},{"id":"227","span":{"begin":286,"end":294},"obj":"Species"},{"id":"228","span":{"begin":683,"end":691},"obj":"Species"},{"id":"255","span":{"begin":16,"end":19},"obj":"Species"},{"id":"256","span":{"begin":151,"end":154},"obj":"Species"},{"id":"257","span":{"begin":198,"end":201},"obj":"Species"},{"id":"258","span":{"begin":336,"end":339},"obj":"Species"},{"id":"259","span":{"begin":486,"end":489},"obj":"Species"},{"id":"260","span":{"begin":512,"end":515},"obj":"Species"},{"id":"279","span":{"begin":74,"end":82},"obj":"Disease"},{"id":"280","span":{"begin":353,"end":362},"obj":"Disease"},{"id":"281","span":{"begin":429,"end":442},"obj":"Disease"},{"id":"282","span":{"begin":446,"end":454},"obj":"Disease"},{"id":"283","span":{"begin":494,"end":499},"obj":"Disease"},{"id":"284","span":{"begin":552,"end":560},"obj":"Disease"},{"id":"285","span":{"begin":623,"end":631},"obj":"Disease"},{"id":"286","span":{"begin":670,"end":682},"obj":"Disease"}],"attributes":[{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"Tax:9606"},{"id":"A226","pred":"tao:has_database_id","subj":"226","obj":"Tax:9606"},{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"Tax:9606"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"Tax:9606"},{"id":"A255","pred":"tao:has_database_id","subj":"255","obj":"Tax:10407"},{"id":"A256","pred":"tao:has_database_id","subj":"256","obj":"Tax:10407"},{"id":"A257","pred":"tao:has_database_id","subj":"257","obj":"Tax:10407"},{"id":"A258","pred":"tao:has_database_id","subj":"258","obj":"Tax:10407"},{"id":"A259","pred":"tao:has_database_id","subj":"259","obj":"Tax:10407"},{"id":"A260","pred":"tao:has_database_id","subj":"260","obj":"Tax:10407"},{"id":"A279","pred":"tao:has_database_id","subj":"279","obj":"MESH:C000657245"},{"id":"A280","pred":"tao:has_database_id","subj":"280","obj":"MESH:D003643"},{"id":"A281","pred":"tao:has_database_id","subj":"281","obj":"MESH:D006509"},{"id":"A282","pred":"tao:has_database_id","subj":"282","obj":"MESH:C000657245"},{"id":"A283","pred":"tao:has_database_id","subj":"283","obj":"MESH:C000657245"},{"id":"A284","pred":"tao:has_database_id","subj":"284","obj":"MESH:C000657245"},{"id":"A285","pred":"tao:has_database_id","subj":"285","obj":"MESH:C000657245"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"MESH:D006509"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chen et al. 10 HBV Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China 12.2% (15/123) of patients were HBV infected\nA higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)\nTotal bilirubin level was higher in patients with comorbid HBV\nPatients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%) Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T65","span":{"begin":74,"end":82},"obj":"Disease"},{"id":"T66","span":{"begin":433,"end":442},"obj":"Disease"},{"id":"T67","span":{"begin":446,"end":454},"obj":"Disease"},{"id":"T68","span":{"begin":494,"end":502},"obj":"Disease"},{"id":"T69","span":{"begin":552,"end":560},"obj":"Disease"},{"id":"T70","span":{"begin":623,"end":631},"obj":"Disease"},{"id":"T71","span":{"begin":711,"end":720},"obj":"Disease"}],"attributes":[{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0005155"}],"text":"Chen et al. 10 HBV Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China 12.2% (15/123) of patients were HBV infected\nA higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)\nTotal bilirubin level was higher in patients with comorbid HBV\nPatients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%) Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T54","span":{"begin":86,"end":87},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T55","span":{"begin":164,"end":165},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T56","span":{"begin":212,"end":213},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T57","span":{"begin":344,"end":345},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Chen et al. 10 HBV Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China 12.2% (15/123) of patients were HBV infected\nA higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)\nTotal bilirubin level was higher in patients with comorbid HBV\nPatients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%) Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":256,"end":265},"obj":"Chemical"},{"id":"T10","span":{"begin":572,"end":583},"obj":"Chemical"},{"id":"T11","span":{"begin":585,"end":600},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Chen et al. 10 HBV Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China 12.2% (15/123) of patients were HBV infected\nA higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)\nTotal bilirubin level was higher in patients with comorbid HBV\nPatients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%) Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-sentences","denotations":[{"id":"T35","span":{"begin":0,"end":11},"obj":"Sentence"},{"id":"T36","span":{"begin":12,"end":163},"obj":"Sentence"},{"id":"T37","span":{"begin":164,"end":249},"obj":"Sentence"},{"id":"T38","span":{"begin":250,"end":312},"obj":"Sentence"},{"id":"T39","span":{"begin":313,"end":502},"obj":"Sentence"},{"id":"T40","span":{"begin":503,"end":601},"obj":"Sentence"},{"id":"T41","span":{"begin":602,"end":720},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chen et al. 10 HBV Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China 12.2% (15/123) of patients were HBV infected\nA higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)\nTotal bilirubin level was higher in patients with comorbid HBV\nPatients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%) Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T15","span":{"begin":711,"end":720},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0001394"}],"text":"Chen et al. 10 HBV Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China 12.2% (15/123) of patients were HBV infected\nA higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)\nTotal bilirubin level was higher in patients with comorbid HBV\nPatients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%) Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}